LU88749I2 - TACRINE et ses dérivés pharmaceutiquement acceptables (COGNEX) - Google Patents

TACRINE et ses dérivés pharmaceutiquement acceptables (COGNEX)

Info

Publication number
LU88749I2
LU88749I2 LU88749C LU88749C LU88749I2 LU 88749 I2 LU88749 I2 LU 88749I2 LU 88749 C LU88749 C LU 88749C LU 88749 C LU88749 C LU 88749C LU 88749 I2 LU88749 I2 LU 88749I2
Authority
LU
Luxembourg
Prior art keywords
hydrogen
double bond
substituent
pharmaceutically acceptable
ethoxy
Prior art date
Application number
LU88749C
Other languages
English (en)
Original Assignee
Summers William Koopmans
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summers William Koopmans filed Critical Summers William Koopmans
Publication of LU88749I2 publication Critical patent/LU88749I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
LU88749C 1986-10-01 1987-09-28 TACRINE et ses dérivés pharmaceutiquement acceptables (COGNEX) LU88749I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91407686A 1986-10-01 1986-10-01
US07/098,871 US4816456A (en) 1986-10-01 1987-09-24 Administration of monoamine acridines in cholinergic neuronal deficit states

Publications (1)

Publication Number Publication Date
LU88749I2 true LU88749I2 (fr) 1996-08-23

Family

ID=26795215

Family Applications (1)

Application Number Title Priority Date Filing Date
LU88749C LU88749I2 (fr) 1986-10-01 1987-09-28 TACRINE et ses dérivés pharmaceutiquement acceptables (COGNEX)

Country Status (12)

Country Link
US (1) US4816456A (fr)
EP (2) EP0328535B1 (fr)
JP (1) JPH0655725B2 (fr)
AT (1) ATE106245T1 (fr)
AU (2) AU621035B2 (fr)
CA (1) CA1335813C (fr)
DE (2) DE3789967T2 (fr)
DK (1) DK295888A (fr)
FI (1) FI891548A0 (fr)
LU (1) LU88749I2 (fr)
MX (1) MX9203762A (fr)
WO (1) WO1988002256A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4789678A (en) * 1986-08-25 1988-12-06 Hoechst-Roussel Pharmaceuticals, Inc. Memory enhancing α-alkyl-4-amino-3-quinolinemethanols and 1-(4-aralkylamino-3-quinolinyl)alkanones and related compounds
US4897400A (en) * 1987-02-13 1990-01-30 Hoeschst-Roussel Pharmaceuticals, Inc. 9-amino-1,4-ethano-1,2,3,4-tetrahydroacridine and related compounds useful for incresing the cholinergic function in a mammal
PH25124A (en) * 1987-03-17 1991-02-19 Hoechst Roussel Pharma Substituted 9-amino-tetrahydro acridines and related compounds
US6075144A (en) 1987-04-20 2000-06-13 Hoechst Marion Roussel, Inc. 9-hydroxyamino tetrahydroacridine and related compounds
US5037833A (en) * 1988-07-25 1991-08-06 Hoechst-Roussel Pharmaceuticals Inc. N-[substituted alkylidene]fused-bicycloalkylidene quinolinamines useful for enhancing the cholinergic function in a mammal
US5013741A (en) * 1987-09-08 1991-05-07 Hoechst-Roussel Pharmaceuticals Incorporated N-[substituted alkylidene]-1,2,3,4-tetrahydro-9-acridinamines useful for enhancing the cholinergic function in a mammal
US5008853A (en) 1987-12-02 1991-04-16 Xerox Corporation Representation of collaborative multi-user activities relative to shared structured data objects in a networked workstation environment
US4985430A (en) 1987-12-03 1991-01-15 Mitsubishi Kasei Corporation 9-acylamino-tetrahydroacridine derivatives and memory enhancing agent containing said derivative as active ingredient
US5019395A (en) * 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
IE62871B1 (en) * 1988-03-08 1995-03-08 Warner Lambert Co Compositions with enhanced penetration
AU621416B2 (en) * 1988-11-16 1992-03-12 Hoechst Marion Roussel, Inc. Hydroxy-1,2,3,4-tetrahydroaminoacridines, a process for their preparation and their use as medicaments
FR2651230B1 (fr) * 1989-08-25 1992-03-13 Synthese Rech Derives de la 5-amino-1,2,3,4 tetrahydro-acridine et applications comme medicaments.
US4994452A (en) * 1989-11-28 1991-02-19 Hoechst-Roussel Pharmaceuticals Inc. Hexahydro-1H-quino[4,3,2-ef][1,4]benzoxazepines and related compounds
US5112829A (en) * 1989-11-28 1992-05-12 Hoechst-Roussel Pharmaceuticals Inc. Hexahydro-1H-quino[4,3,2-ef][1,4]benzoxazepines and related compounds
US5508280A (en) * 1990-05-18 1996-04-16 Merrell Pharmaceuticals, Inc. 5H-Dibenzo (A,D) cycloheptenes as muscarinic receptor antagonists
US5610155A (en) * 1992-04-09 1997-03-11 Dr. Karl Thomae Gmbh Condensed diazepinones, processes for preparing them and agents containing these compounds for treating diseases of the central nervous system and for promoting cerebral blood circulation
US5466696A (en) * 1992-09-10 1995-11-14 Warner Lambert Company Tacrine and cytochrome P450 oxidase inhibitors and methods of use
US5422350A (en) * 1992-09-10 1995-06-06 Warner-Lambert Company Nitrogen substituted acridine and cytochrome P450 inhibitors and methods of use
US5434170A (en) * 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
DE19533089C1 (de) * 1995-09-07 1997-05-22 Hexal Ag Tacrin-Pflaster
US20100210590A1 (en) * 1995-09-27 2010-08-19 Northwestern University Compositions and treatments for seizure-related disorders
GB9524346D0 (en) * 1995-11-29 1996-01-31 Univ Strathclyde Polycyclic compounds
US5783584A (en) * 1995-12-11 1998-07-21 Mayo Foundation For Medical Education And Research THA analogs useful as cholinesterase inhibitors
US5929093A (en) * 1996-06-13 1999-07-27 Mayo Foundation For Medical Education And Research Bifunctional acetylcholinesterase reactivators
GB9924941D0 (en) * 1999-10-22 1999-12-22 Univ Manchester Treatment of dyskinesia
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
WO2001083425A1 (fr) * 2000-05-04 2001-11-08 Warner-Lambert Company Procede d'inhibition de l'agregation de proteines amyloides et d'imagerie de depots amyloides faisant appel a des derives amino-indanes
CN100339070C (zh) * 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
US20050222123A1 (en) 2004-01-27 2005-10-06 North Shore-Long Island Jewish Research Institute Cholinesterase inhibitors for treating inflammation
EP1779867A4 (fr) * 2004-07-01 2009-12-02 Eisai R&D Man Co Ltd Promoteur de la régénérescence nerveuse
ATE523199T1 (de) * 2004-11-02 2011-09-15 Univ Northwestern Pyridazinverbindungen und verfahren
ES2328384T3 (es) * 2004-11-23 2009-11-12 Warner-Lambert Company Llc Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
CA2650711A1 (fr) * 2006-04-28 2007-11-08 Northwestern University Compositions et traitements utilisant des pyridazines et des inhibiteurs de cholinesterase
EP2533645B1 (fr) 2010-02-09 2016-07-27 The Johns Hopkins University Procédés et compositions pour améliorer la fonction cognitive
AU2011328993B2 (en) 2010-11-15 2017-03-02 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
RU2623049C2 (ru) 2011-03-04 2017-06-21 Бектон, Дикинсон энд Кампани Устройство для взятия крови, содержащее ингибитор лизофосфолипазы
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CA2904767C (fr) 2013-03-15 2022-06-21 Agenebio, Inc. Procedes et compositions pour ameliorer la fonction cognitive
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
EP4032889B1 (fr) 2013-12-20 2026-05-06 Agenebio, Inc. Dérivés de benzodiazépine, compositions et méthodes de traitement de déficience cognitive
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
EP3310785B1 (fr) 2015-06-19 2024-11-20 Agenebio, Inc. Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20210292293A1 (en) * 2018-02-19 2021-09-23 Kuniko KUSAMA Novel compound based on valerolactone and medicine
AU2019288382B2 (en) 2018-06-19 2024-07-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
KR101953366B1 (ko) 2018-12-26 2019-02-28 정종문 침향을 포함하는 기억력 및 인지능력을 향상시키는 기능성 건강식품 및 이의 제조방법
EP4572852A1 (fr) 2022-08-19 2025-06-25 Agenebio, Inc. Dérivés de benzoazépine, compositions et méthodes de traitement de déficience cognitive

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1629873A (en) * 1919-07-08 1927-05-24 Ig Farbenindustrie Ag Acridine derivatives and process of making same
US2083908A (en) * 1933-03-23 1937-06-15 Hata Sahachiro Method of preparing 9-amino-3, 6-dimethoxy-10-methyl-acridinium chlorides
US2083903A (en) * 1936-04-27 1937-06-15 Gerald William G Fitz Tire chain
US3043842A (en) * 1959-02-09 1962-07-10 Smith Kline French Lab Substituted acridans
CH420150A (de) * 1961-12-18 1966-09-15 Siegfried Ag Verfahren zur Herstellung von 10-Aminoalkyl-5,5-dialkylacridanen
NL6603826A (fr) * 1965-03-24 1966-09-26
DE1251764B (de) * 1965-08-18 1967-10-12 C H Boehnnger Sohn Ingelheim/ Rhein Verfahren zur Herstellung von antimikrobiell wirksamen 12 3,4-Tetra hydro 9 -ammo acridmiumverbmdungen
US3489837A (en) * 1968-07-11 1970-01-13 Leroy J Hyman Synergistic antiseptic composition consisting of 9-aminoacridine hydrochloride and benzethonium chloride
EP0179383B1 (fr) * 1984-10-25 1991-05-29 Hoechst-Roussel Pharmaceuticals Incorporated 9-Amino-1,2,3,4-tétrahydroacridine-1-ol et composés apparentés, procédé pour leur préparation et leur utilisation comme médicaments
US4631286A (en) * 1984-10-25 1986-12-23 Hoechst-Roussel Pharmaceuticals Inc. 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds

Also Published As

Publication number Publication date
DE19575031I2 (de) 2003-05-22
FI891548A7 (fi) 1989-03-31
EP0328535A1 (fr) 1989-08-23
JPH02500975A (ja) 1990-04-05
AU671933B2 (en) 1996-09-12
DE3789967T2 (de) 1994-09-22
JPH0655725B2 (ja) 1994-07-27
MX9203762A (es) 1992-09-01
ATE106245T1 (de) 1994-06-15
AU7888694A (en) 1995-02-09
CA1335813C (fr) 1995-06-06
EP0328535B1 (fr) 1994-06-01
US4816456A (en) 1989-03-28
EP0595365A1 (fr) 1994-05-04
WO1988002256A1 (fr) 1988-04-07
DK295888A (da) 1988-06-07
FI891548A0 (fi) 1989-03-31
AU621035B2 (en) 1992-03-05
HK1001669A1 (en) 1998-07-03
DK295888D0 (da) 1988-05-31
EP0328535A4 (en) 1991-05-22
AU8070787A (en) 1988-04-21
DE3789967D1 (de) 1994-07-07

Similar Documents

Publication Publication Date Title
AU671933B2 (en) The administration of monoamine acridine in cholinergic neuronal deficit states
MY108885A (en) Heterocyclic-cyclic amine derivatives.
NO175592C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive xantiner
ES468119A1 (es) Un procedimiento para la preparacion de triazinas
IL103944A (en) Piperazine derivatives, their preparation and pharmaceutical compositions containing them
ATE56721T1 (de) Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel.
EP0614661A3 (fr) Dérivés de la benzylidène et la cinnamylidène-Malononitrile pour l'inhibition des processus de prolifération dans les cellules des mammifères.
ATE224T1 (de) 1,2-dihydro-chinolin-2-on-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel.
LU90758I2 (fr) Almotriptan et ses sels pharmaceutiquement acceptables
MY104335A (en) 4-aminophridine deravatives
NO995638D0 (no) Heterobicykliske forbindelser til fremstilling av pyridonkarboksylsyrederivater
TR199902350T2 (xx) Yeni piridin t�revleri ve onlardan olu�an farmakotik bile�imler.
MY129935A (en) Dihydropyridine derivatives useful in antitumor therapy
NO882334L (no) Fremgangsmaate for fremstilling av terapeutisk aktive alkansulfonanilid-derivater.
TW350838B (en) Quinoline derivatives
ES455741A1 (es) Un procedimiento para la preparacion de nuevos derivados de 1,3-bencenodimetanol.
ATE138266T1 (de) Verwendung von xanthinen zur herstellung von arzneimitteln zur hemmung der vermehrung menschlicher retroviren
ATE123487T1 (de) Derivate der kaffeinsäure und sie enthaltende pharmazeutische zusammensetzungen.
ATE278676T1 (de) Imdazol-derivate, deren herstellung und deren verwendung als s-adenosylmethionin decarboxylase (=samdc) inhibitoren
DE59206593D1 (de) Verwendung von 2-Iminothiazolidin-4-onderivaten als neuartige Arzneimittelwirkstoffe
ATE70838T1 (de) Substituierte 3-aminosydnonimine, verfahren zu ihrer herstellung und ihre verwendung.
NO932418L (no) Pyrimidinderivater, fremgangsmaate for deres fremstilling og terapeutiske anvendelse derav
FR2694557B1 (fr) Dérivés de tétrahydronaphtalène, leur préparation, et leur application en thérapeutique.
ES2056025A1 (es) Nuevos derivados de indol.
JPS5278896A (en) Synthesis of 2-substituted thioadenosines